HBPCF (Helix BioPharma) ROC (Joel Greenblatt) %: -193,200.00% (As of Apr. 2026)


HBPCF Helix BioPharma Corp HBPCF
28 GF Score
Price $1.71
View Full Analysis

What is Helix BioPharma ROC (Joel Greenblatt) %?

Helix BioPharma HBPCF 28 ROC (Joel Greenblatt) % is -193,200.00% as of Apr. 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100. Among 1,325 Biotechnology companies, Helix BioPharma ranks worse than 98.64% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Helix BioPharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2026 was -193,200.00%.

The historical rank and industry rank for Helix BioPharma's ROC (Joel Greenblatt) % or its related term are showing as below:

HBPCF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -109733.33   Med: -4973.44   Max: -1996.75
Current: -109733.33

During the past 13 years, Helix BioPharma's highest ROC (Joel Greenblatt) % was -1996.75%. The lowest was -109733.33%. And the median was -4973.44%.

HBPCF's ROC (Joel Greenblatt) % is ranked worse than
98.64% of 1325 companies
in the Biotechnology industry
Industry Median: -297.52 vs HBPCF: -109733.33

Helix BioPharma's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -53.70% per year.


Helix BioPharma  (OTCPK:HBPCF) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Helix BioPharma ROC (Joel Greenblatt) % Related Terms


Helix BioPharma ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Helix BioPharma's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix BioPharma ROC (Joel Greenblatt) % Chart

Helix BioPharma Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6,936.36 -15,569.23 -18,273.08 -27,551.02 -28,103.70

Helix BioPharma Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -72,933.33 -69,000.00 -142,600.00 -199,200.00 -193,200.00

HBPCF vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Helix BioPharma's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helix BioPharma ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's ROC (Joel Greenblatt) % falls into.


HBPCF
28GF Score
Helix BioPharma Corp HBPCF
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helix BioPharma ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jan. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + -0.001) - (2.037 + 0 + 0)
=-2.038

Working Capital(Q: Apr. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (1.935 + 0 + 2.67)
=-4.605

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Helix BioPharma for the quarter that ended in Apr. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Apr. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jan. 2026  Q: Apr. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.932/( ( (0.001 + max(-2.038, 0)) + (0.001 + max(-4.605, 0)) )/ 2 )
=-1.932/( ( 0.001 + 0.001 )/ 2 )
=-1.932/0.001
=-193,200.00 %

Note: The EBIT data used here is four times the quarterly (Apr. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -193,200.00% mean?
Helix BioPharma (HBPCF) has a ROC (Joel Greenblatt) % of -193,200.00% as of Apr. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Helix BioPharma and its competitors. According to the industry distribution chart, Helix BioPharma ranks #1307 out of 1325 companies in the Biotechnology industry, placing it in the top 98.6%.
Is Helix BioPharma's ROC (Joel Greenblatt) % too high?
Helix BioPharma's current ROC (Joel Greenblatt) % is -193,200.00%. Based on the distribution chart, Helix BioPharma ranks #1307 out of 1325 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helix BioPharma ranks #1307 out of 1325 companies for ROC (Joel Greenblatt) %. This places Helix BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Helix BioPharma and its competitors. Helix BioPharma's current ROC (Joel Greenblatt) % is -193,200.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current ROC (Joel Greenblatt) % of -193,200.00%. The current ROC (Joel Greenblatt) % is -193,200.00%. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current ROC (Joel Greenblatt) % is -193,200.00% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helix BioPharma Business Description

Other Exchanges HBP0:GermanyHBP:Canada
Address 40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score

Get the complete analysis for HBPCF

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price